Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.

Hopewell, J C; Seedorf, U; Farrall, M; Parish, S; Kyriakou, T; Goel, A; Hamsten, A; Collins, R; Watkins, H; Clarke, R

Hopewell, J C; Seedorf, U; Farrall, M; Parish, S; Kyriakou, T; Goel, A; Hamsten, A; Collins, R; Watkins, H; Clarke, R.

Affiliation

Hopewell JC; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

J Intern Med ; 276(3): 260-8, 2014 Sep.

Article in En | MEDLINE | ID: mdl-24372611

Subject(s)

Coronary Disease/etiology; Lipoprotein(a)/metabolism; Apoprotein(a)/chemistry; Apoprotein(a)/metabolism; Case-Control Studies; Coronary Disease/blood; Female; Humans; Lipoprotein(a)/chemistry; Male; Middle Aged; Protein Isoforms/metabolism; Risk Factors

Key words

apolipoprotein(a); coronary heart disease; isoform size; lipoprotein(a)

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lipoprotein(a) / Coronary Disease Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: J Intern Med Journal subject: MEDICINA INTERNA Year: 2014 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google